Medtronic Expands Stealth AXiS To Cranial, ENT

Medtronic said on March 28, 2026 the U.S. FDA cleared its Stealth AXiS surgical system for cranial and ear, nose and throat procedures, expanding the platform beyond a February spine indication. The system combines navigation, imaging, robotics and uses AI to auto-generate brain maps; the company also cut its fiscal 2026 profit forecast to $5.50–$5.54 after a roughly $157 million one-time charge.